Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAIN-AF: Rivaroxaban for Stroke and Cognitive Decline in AF
NCT02387229Phase 3Terminated
- Sponsor
- Montréal Heart Institute
- Start
- Mar 2015
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rivaroxaban in Atrial fibrillation (AFib), sponsored by Montréal Heart Institute. Started Mar 2015; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02387229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387229.